The activity of crizotinib in chemo-refractory MET-amplified esogastric adenocarcinomas: results from the AcSé-crizotinib program.

Congress : ASCO

Authors : Thomas Aparicio, Nathalie Cozic, Christelle De La Fouchardière, Emeline Meriaux, Jérôme Edouard Plaza, Laurent Mineur, Rosine Guimbaud, Emmanuelle Samalin, Florence Mary, Thierry Lecomte, Carlos Alberto Gomez-Roca, Paul Arthur Haineaux, Alain Gratet, Janick Selves, Yves Menu, Nikias Colignon, Céline Mahier - Ait Oukhatar, Frédéric Legrand, Gilles Vassal

Experts group or program : Médecine personnalisée


Crizotinib (czb) is only registered for treating ALK and ROS1-translocated lung cancer. However, Czb is also a MET inhibitor. Several malignancies are characterized by MET amplification (amp). Czb activity in MET-amplified (+) tumors was explored within the French National Cancer Institute (INCa) AcSé program. This included access to tumor molecular diagnoses and an exploratory multi-tumor 2-stage design phase II trial. We herein report the results in patients (pts) with esogastric MET+ adenocarcinomas (adenoK).

En savoir plus